

Special Issue

Next Generation Cytopathology: Current Status and Future Prospects

Message from the Guest Editor

Cytopathology is a key specialty in identifying and managing various illnesses, and recent advances have been astounding. The advancement of liquid-based cytology and molecular testing has enabled earlier and more accurate diagnoses and tailored medicines based on genetic abnormalities, improving outcomes for numerous individuals. Overall, the area of cytopathology is primed for further advancement and innovation in the following years, with the potential to improve patient outcomes and save lives. This Special Issue, entitled "Cytopathology: Current Status and Future Prospects," aims to recruit high-quality original articles or comprehensive reviews focusing on cytopathology and advances in the following subjects:

- New insights and experience in international reporting systems;
- Application of new molecular or ancillary testing in cytopathology;
- The utilization of digital pathology;
- Rapid on-site evaluation and potential pitfalls;
- Machine learning models for cytopathology;
- Comprehensive comparison for different methods or interobserver variability.

Guest Editor

Dr. Chien-Chin Chen

1. Department of Cosmetic Science, Chia Nan University of Pharmacy and Science, Tainan, Taiwan
2. Department of Pathology, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan
3. Department of Biotechnology and Bioindustry Sciences, College of Bioscience and Biotechnology, National Cheng Kung University, Tainan, Taiwan
4. Ph.D. Program in Translational Medicine, Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Tainan, Taiwan

Deadline for manuscript submissions

closed (28 February 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/170957

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).